Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 25-33 , March 2009

Lessons from VTE registries: the RIETE experience

  • Manuel Monreal, PhD (Professor of Medicine)

      Affiliations

    • Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 669675313; Fax: +34 934978843.
    • ,
  • Javier Trujillo-Santos, PhD (Doctor)

      Affiliations

    • Department of Internal Medicine, Hospital Universitario Santa María del Rosell, Cartagena, Murcia, Spain

References 

  1. Monreal M, Falgá C, Valdés M, et al., RIETE Investigators  Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE Registry. J Thromb Haemost. 2006;4:1950–1956
  2. Kearon C, Kahn S, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn.). Chest. 2008;133:454S–545S
  3. Levitan N, Dowlati A, Remick S, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78:285–291
  4. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240–1245
  5. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7
  6. Sorensen H, Mellemkjaer L, Olsen J, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850
  7. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn.). Chest. 2008;133:381S–453S
  8. Trujillo-Santos J, Prandoni P, Rivron-Guillot K, et al., RIETE Investigators  Clinical outcome in patients with venous thromboembolism and hidden cancer. Findings from the RIETE Registry. J Thromb Haemost. 2008;6:251–255
  9. Gore JM, Appelbaum JS, Greene HL, et al. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med. 1982;96:556–560
  10. Goldberg RJ, Seneff M, Gore JM, et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med. 1987;147:251–253
  11. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351:1077–1080
  12. Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169–1173
  13. Prandoni P, Lensing AWA, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128–1133
  14. Piccioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol. 2001;106:13–17
  15. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancer associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850
  16. Lee AYY. Screening for occult cancer in patients with idiopathic venous thromboembolism: no. J Thromb Haemost. 2003;1:2273–2274
  17. Monreal M, Fernandez-Llamazares J, Perandreu J, et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316–1318
  18. Piccioli A, Prandoni P. Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost. 2003;1:2271–2272
  19. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med. 2002;162:1729–1735
  20. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;34:146–153
  21. Deitcher SR, Kessler CM, Merli G, et al., ONCENOX Investigators  Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12:389–396
  22. Hull RD, Pineo GF, Brant RF, et al., LITE Trial Investigators  Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007;120:72–82
  23. Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:435–439
  24. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078–3083
  25. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488
  26. Kearon C. Long-term management of patients after venous thrombo-embolism. Circulation. 2004;110(Suppl. I):I-10–I-18
  27. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457–460
  28. Ruiz-Giménez N, Suárez C, González R, et al., RIETE Investigators  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31
  29. Trujillo-Santos J, diMicco P, Iannuzzo MT, et al., RIETE Investigators  Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:905–911
  30. Kasuga I, Makino S, Kiyokawa H, et al. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer. 2001;92:2399–2405
  31. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations. A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23:6240–6248
  32. Shankar A, Wang JJ, Rochtchina E, et al. Association between circulating white blood cell count and cancer mortality. Arch Intern Med. 2006;166:188–194
  33. Gripp S, Moeeler S, Bölke E, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007;25:3313–3320
  34. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patient's predictions of prognosis and their treatment preferences. JAMA. 1998;279:1709–1714
  35. Christakis NA, Lamont EB. Extent and determinants of error in doctor's prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320:469–472
  36. Lamont EB, Christakis NA. Complexities in prognostication in advanced cancer. JAMA. 2003;290:98–104
  37. Vigano A, Dorgan M, Buckingham J. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med. 2000;14:363–374
  38. Prandoni P, Trujillo-Santos J, Surico T, et al., RIETE Investigators  Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE Registry. Haematologica. 2008;93:1432–1434

PII: S1521-6926(08)00108-4

doi: 10.1016/j.beha.2008.12.003

Best Practice & Research Clinical Haematology
Volume 22, Issue 1 , Pages 25-33 , March 2009

Article Tools

* Image Usage & Resolution